MEDVi vs. Noom Med: prices, fine print, and the honest verdict

Tirzepatide pricing

MEDVi: $399 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $249/mo (12-month plan). Noom Med does not offer tirzepatide.

Semaglutide pricing

On semaglutide, Noom Med wins at $199 versus $299 all-in — $100/mo apart. MEDVi: Semaglutide runs $299 a month all-in at the standing rate ($179 on intro/plan terms). Noom Med: Semaglutide runs $199 a month all-in — capped at 0.6 mg, a quarter of the trial dose.

Transparency

MEDVi: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. Noom Med: Source-verified (verified 2026-08-08); names its pharmacy — Tailor Made Compounding (named). In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

MEDVi: 12-month plan for the lowest rate; 12-month plan applies to lowest rate. Noom Med: 12-week cycles; 12-week billing cycles.

Two ladders, side by side

The 2.5-to-10 mg climb is the honest stress test: MEDVi holds $399 on every rung (four-month titration: exactly $1,596). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

The semaglutide board

On semaglutide, Noom Med prices at $199 against $299 all-in. Both sit against a verified field floor of $133 and Wegovy's flat $349 brand rate; dual-molecule pricing also sets each program's internal switch cost when a plateau raises the tirzepatide question.

The five normalizations, applied to this pair

1 · All-in, not advertised. MEDVi's ranked figure is $399, with no membership to add; Noom Med publishes no figure to normalize. 2 · Maintenance basis. MEDVi is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. MEDVi: standing $399, prepaid $249 effective (12-month plan) — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. MEDVi: source-verified, read 2026-08-05; Noom Med: source-verified, read 2026-08-08. 5 · Pharmacy weighed. MEDVi names no pharmacy; Noom Med names Tailor Made Compounding (named) — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

MEDVi: no membership — the medication figure is the billed figure; prepaid 12-month plan at $249/mo effective; 12-month plan applies to lowest rate; commitment: 12-month plan for the lowest rate. Noom Med: no membership — the medication figure is the billed figure; 12-week billing cycles; commitment: 12-week cycles. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

MEDVi carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Noom Med carries source-verified pricing (last read 2026-08-08); pharmacy disclosure is its strong suit — Tailor Made Compounding (named), named 503A/503B partner. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

Neither program locks the door: a MEDVi-to-Noom Med move is a new intake, a new prescription at the new pharmacy, and a written cancellation at the old shop — typically a one-to-two-week overlap if you time the last fill. What does not move with you: prepaid months, membership balances, and any dose paperwork, so re-state your current rung clearly at the new intake.

Refills, shipping, and the week-to-week reality

Past the pricing page, the operational facts are what a subscriber lives with: MEDVi: shipping included; consultation included; async visit model. Noom Med: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick MEDVi if you want a price that survives titration; you'll prepay for the $249 effective rate. Pick Noom Med if the semaglutide line is cheaper here; a named pharmacy is non-negotiable for you. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

Two programs never exhaust the market — the nearest substitutes on the verified board are Remedy Meds at $399 (flat, no membership); Eden at $408 (dose-scaled, $99 membership included); Fridays at $359 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $600/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

With incomplete published pricing on one or both sides, get current figures in writing before enrolling with either. Both records, with dates and sources, live in the pricing database.